Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick A Sirgel

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|June 19, 2010
Measuring minimum inhibitory concentrations in mycobacteriaFrederick A Sirgel, Ian J F Wiid, Paul D van Helden
Antimicrobial Agents and Chemotherapy|February 12, 2014
Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutationsMarieta McGrath, Nico C Gey van Pittius, Frederick A Sirgel, et al.
The Journal of Antimicrobial Chemotherapy|May 14, 2014
The pyrazinamide susceptibility breakpoint above which combination therapy failsTawanda Gumbo, Emmanuel Chigutsa, Jotam Pasipanodya, et al.
Plos One|March 26, 2013
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaksFrederick A Sirgel, Robin M Warren, Erik C Böttger, et al.
The Journal of Antimicrobial Chemotherapy|February 24, 2012
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosisFrederick A Sirgel, Robin M Warren, Elizabeth M Streicher, et al.
Chemotherapy|November 23, 2012
embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosisFrederick A Sirgel, Robin M Warren, Elizabeth M Streicher, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2014
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosisEmmanuel Chigutsa, Jotam G Pasipanodya, Marianne E Visser, et al.
The Journal of Antimicrobial Chemotherapy|July 9, 2018
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosisMichael G Whitfield, Robin M Warren, Vanessa Mathys, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2020
Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impactAnnelies Van Rie, Michael G Whitfield, Elise De Vos, et al.
Lancet (London, England)|January 21, 2014
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort studyElize Pietersen, Elisa Ignatius, Elizabeth M Streicher, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|June 19, 2010
Measuring minimum inhibitory concentrations in mycobacteriaFrederick A Sirgel, Ian J F Wiid, Paul D van Helden
Antimicrobial Agents and Chemotherapy|February 12, 2014
Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutationsMarieta McGrath, Nico C Gey van Pittius, Frederick A Sirgel, et al.
The Journal of Antimicrobial Chemotherapy|May 14, 2014
The pyrazinamide susceptibility breakpoint above which combination therapy failsTawanda Gumbo, Emmanuel Chigutsa, Jotam Pasipanodya, et al.
Plos One|March 26, 2013
The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaksFrederick A Sirgel, Robin M Warren, Erik C Böttger, et al.
The Journal of Antimicrobial Chemotherapy|February 24, 2012
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosisFrederick A Sirgel, Robin M Warren, Elizabeth M Streicher, et al.
Chemotherapy|November 23, 2012
embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosisFrederick A Sirgel, Robin M Warren, Elizabeth M Streicher, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2014
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosisEmmanuel Chigutsa, Jotam G Pasipanodya, Marianne E Visser, et al.
The Journal of Antimicrobial Chemotherapy|July 9, 2018
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosisMichael G Whitfield, Robin M Warren, Vanessa Mathys, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2020
Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impactAnnelies Van Rie, Michael G Whitfield, Elise De Vos, et al.
Lancet (London, England)|January 21, 2014
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort studyElize Pietersen, Elisa Ignatius, Elizabeth M Streicher, et al.
Pageof 3